Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-4 of 4 for your search:
Drug:
palonosetron hydrochloride
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)(COMPLETED)
Phase:
Phase IV
Type:
Supportive care
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
P04594
, NCT00687011
2.
Phase III Randomized Study of APF530 Versus Palonosetron Hydrochloride in Combination With Dexamethasone For Prophylaxis of Acute- and Delayed-Onset, Chemotherapy-Induced Nausea and Vomiting in Cancer Patients Undergoing Moderately or Highly Emetogenic Chemotherapy
Phase:
Phase III
Type:
Supportive care
Status:
Completed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
APP-C2006-01
, NCT00343460
3.
Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
Phase:
Phase II, Phase I
Type:
Supportive care, Treatment
Status:
Closed
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
2005-0506
, NCT00412425
4.
Phase II Study of Aprepitant, Palonosetron Hydrochloride, and Dexamethasone in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving FOLFOX or FOLFIRI Chemotherapy for Metastatic Colorectal Cancer
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
OHSU-SOL-06006-LM
, 2302, OHSU-IRB-2302, NCT00381862
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute